Enterprise Value

511.7M

Cash

278.6M

Avg Qtr Burn

-29.67M

Short % of Float

1.58%

Insider Ownership

29.00%

Institutional Own.

41.17%

Qtr Updated

12/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
ZYNLONTA (Loncastuximab Tesirine) (CD19) Details
Follicular lymphoma, Mantle cell lymphoma, Diffuse large B cell lymphoma

Approved

Update

Camidanlumab Tesirine (CD25) Details
Solid tumor/s, Cancer, Hodgkin Lymphoma

BLA

Submission

Phase 3

Data readout

ZYNLONTA + Rituximab Details
Blood cancer, Follicular lymphoma

Phase 2

Update

ZYNLONTA (Loncastuximab Tesirine) (CD19) Details
Cancer, Blood cancer, Diffuse large B cell lymphoma

Phase 2

Update

Phase 1b

Data readout

ZYNLONTA (Loncastuximab Tesirine) (CD19) Details
Non-Hodgkin lymphoma, Blood cancer, Cancer

Phase 1b

Data readout

ADCT-602 (CD22) Details
Acute lymphoblastic leukemia

Phase 1a

Data readout

ZYNLONTA (Loncastuximab Tesirine) (CD19) Details
Cancer, Diffuse large B cell lymphoma

Failed

Discontinued

Failed

Discontinued